Back to Directory
Mecasermin
Performance & EnduranceRecombinant IGF-1 for severe primary IGF-1 deficiency when GH ineffective.
Key Benefits
- ✓Treats severe primary IGF-1 deficiency
- ✓Promotes growth when GH ineffective
- ✓Rare disease treatment
- ✓IGF-1 replacement
Dosing Information
Dosage Range
0.04-0.12 mg/kg
Frequency
Twice daily
Typical Duration
Until growth complete
Detailed Protocol
Administered via subcutaneous injection twice daily shortly before or after meals (reduces hypoglycemia risk). Dose based on weight. Specialized use. Prescription only.
About Mecasermin
Mecasermin (Increlex) is recombinant human insulin-like growth factor-1. FDA-approved for severe primary IGF-1 deficiency (growth hormone gene deletion, GH receptor mutations, or anti-GH antibodies) when GH treatment ineffective.
Research Notes
FDA-approved in 2005 for severe primary IGFD. Orphan drug for rare condition. Used when GH ineffective due to receptor mutations or antibodies. Requires careful glucose monitoring.
Potential Side Effects
- •Hypoglycemia (common)
- •Tonsillar hypertrophy
- •Headache
- •Intracranial hypertension risk
- •Jaw growth
- •Requires monitoring
Always consult with a healthcare professional before starting any peptide therapy.